Product Description
Asunaprevir is an orally bioavailable inhibitor of the nonstructural protein 3 (NS3), with potential activity against hepatitis C virus (HCV). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Asunaprevir)
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Canada | Chile | Colombia | Japan | Korea | New Zealand | Peru | Russia | Taiwan | Turkey
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Unknown Location
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20132226 | P3 |
Active, not recruiting |
Hepatitis C, Chronic |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
| CTR20132850 | P3 |
Active, not recruiting |
Hepatitis C, Chronic |
None |
2025-04-29 |
Patient Enrollment |